13G Filing: Partner Fund Management and Jounce Therapeutics Inc (JNCE)

Jounce Therapeutics Inc (NASDAQ:JNCE): Christopher Medlock James’ Partner Fund Management filed an amended 13D.

You can check out Partner Fund Management’s latest holdings and filings here.

Please follow Partner Fund Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Partner Fund Management or update its stock holdings.

Christopher Medlock James
Christopher Medlock James
Partner Fund Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Partner Fund Management 0 1,727,943 0 5.4%
Partner Fund Management GP 0 1,727,943 0 5.4%
Partner Investment Management 0 14,265 0 Less%
Partner Investment Management GP 0 14,265 0 Less%
Brian D. Grossman 0 1,742,208 0 5.4%
Christopher M. James 0 1,742,208 0 5.4%
Christopher Medlock James
Christopher Medlock James
Partner Fund Management

Page 1 of 13 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
SCHEDULE 13G
(Rule 13d-102)
Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No.     )*
Jounce Therapeutics, Inc.
(Name of Issuer)
Common stock, par value $0.001 per share
(Title of Class of Securities)

481116101

(CUSIP Number)

September
19, 2017

Date of Event Which Requires Filing of the Statement

Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:

¨ Rule
13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Follow Jounce Therapeutics Inc.